Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OriCAR-017 in relapsed/refractory multiple myeloma
NCT06271252Phase 1Recruiting
- Sponsor
- OriCell Therapeutics
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oricar-017 in multiple myeloma (MM), sponsored by OriCell Therapeutics. Primary endpoints: Maximum tolerated dose at 28 days and Dose-limiting toxicity at 28 days. Started Apr 2024; status: recruiting.
02
Drugs
oricar-017
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06271252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06271252.